Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis

The cholecystokinin 2 receptor (CCK2R/CCKBR) is expressed in gastrointestinal stromal tumours (GISTs). We sought to investigate the role of CCK2R in GIST pathogenesis. Molecular characterization of CCK2R was performed on a heterogeneous cohort of 50 GISTs. In addition, CCK2R expression was evaluated by immunohistochemistry (IHC), using tissue microarray (TMA) containing 292 GISTs, two cases of hyperplasia of interstitial Cajal's cells (ICC) and six gastric microscopic GISTs. Mono‐allelic loss of the CCK2R/11p15 allele was identified in 13.7% of GISTs, having no impact on the level of CCK2R transcript expression. No CCK2R mutations were found. The CCK2Ri4sv, CCK2R splice variant with retention of intron 4 was detected in six of 20 tumours analysed. Wild‐type CCK2R transcripts were commonly expressed (57.1% of cases) and this expression was highly correlated with gastric primary site of GISTs (p < 0.001). At the protein level, expression of CCK2R in incidental ICC hyperplasia and early stages of gastric GIST development was documented, and its gastric association was confirmed on GIST‐TMA by IHC. To explore the in vivo effect of CCK2R activation on tumour growth, gastrin versus placebo was administered intraperitoneally in nude mice carrying human GIST xenografts. The tumour volume was followed for 10 weeks. The effect of this stimulation on tumour cell proliferation/apoptosis was assessed by IHC and KIT/PKC‐θ signalling was evaluated by western blotting (WB). In vivo experiments showed a two‐fold increase in the volume of tumours which were exposed to gastrin in comparison with non‐exposed controls (p = 0.03), with a significant increase in mitotic activity (p = 0.04) and Ki‐67 proliferation index (p = 0.008). By WB, gastrin stimulation resulted in hyper‐activation of KIT and PKC‐θ kinases, and in evident PI3K‐AKT pathway over‐activation. Our results indicate a promoting role of CCK2R on GIST tumourigenesis, particularly in tumours of gastric origin. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  J. Blay,et al.  Incidence of soft tissue sarcoma and beyond , 2012, Cancer.

[2]  R. Sciot,et al.  Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.

[3]  P. Went,et al.  Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. , 2011, Human pathology.

[4]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[5]  B. Rubin,et al.  Neurotensin Receptor 1 Is Expressed in Gastrointestinal Stromal Tumors but Not in Interstitial Cells of Cajal , 2011, PloS one.

[6]  J. Fletcher,et al.  Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size , 2010, The American journal of surgical pathology.

[7]  C. Chao,et al.  Gastrin, inflammation, and carcinogenesis , 2010, Current opinion in endocrinology, diabetes, and obesity.

[8]  A. Kolokoltsov,et al.  CCK2 receptor expression transforms non‐tumorigenic human NCM356 colonic epithelial cells into tumor forming cells , 2009, International journal of cancer.

[9]  T. Graham,et al.  Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo , 2009, Gut.

[10]  L. Miller,et al.  CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours , 2009, Journal of cellular and molecular medicine.

[11]  N. Lemoine,et al.  Pancreatic cancer: molecular pathogenesis and new therapeutic targets , 2009, Nature Reviews Gastroenterology &Hepatology.

[12]  P. Atadja,et al.  High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model , 2009, Clinical Cancer Research.

[13]  L. Terracciano,et al.  Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions , 2008, The American journal of surgical pathology.

[14]  R. Chetty.  Small and microscopically detected gastrointestinal stromal tumours: an overview , 2008, Pathology.

[15]  S. Watson,et al.  Role of gastrin peptides in carcinogenesis. , 2007, Cancer letters.

[16]  A. Varró,et al.  Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo , 2007, Experimental physiology.

[17]  R. Jensen,et al.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. , 2007, Current topics in medicinal chemistry.

[18]  J. Vermeesch,et al.  Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status , 2007, Genes, chromosomes & cancer.

[19]  A. Kolokoltsov,et al.  Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1α expression and tumor growth , 2007, Oncogene.

[20]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[21]  T. Nakajima,et al.  High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.

[22]  A. Kowalski-Chauvel,et al.  An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway. , 2006, Biochimica et biophysica acta.

[23]  C. Seva,et al.  Cholecystokinin and gastrin receptors. , 2006, Physiological reviews.

[24]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[25]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[26]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[27]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[28]  Luis Moroder,et al.  The G‐protein‐coupled CCK2 receptor associates with phospholipase Cγ1 , 2004 .

[29]  N. Socci,et al.  Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.

[30]  A. Hagemeijer,et al.  Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity , 2004, The Journal of pathology.

[31]  S. Watson,et al.  An Antiapoptotic Role for Gastrin and the Gastrin/CCK-2 Receptor in Barrett’s Esophagus , 2004, Cancer Research.

[32]  L. Mazzucchelli,et al.  High expression of peptide receptors as a novel target in gastrointestinal stromal tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  D. Thompson,et al.  Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. , 2003, Gastroenterology.

[34]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[35]  M. Ringnér,et al.  Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. , 2001, Cancer research.

[36]  S. Watson,et al.  Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence , 2000, Gut.

[37]  H. Hellmich,et al.  Human Colorectal Cancers Express a Constitutively Active Cholecystokinin-B/Gastrin Receptor That Stimulates Cell Growth* , 2000, The Journal of Biological Chemistry.

[38]  A. Smith,et al.  Gastrin and Colorectal Cancer , 2000 .

[39]  T. Koh,et al.  Gastrin as a growth factor in the gastrointestinal tract , 2000, Regulatory Peptides.

[40]  S. Watson,et al.  Expression of CCKB/gastrin receptor isoforms in gastro‐intestinal tumour cells , 1998, International journal of cancer.

[41]  H. Friess,et al.  Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. , 1997, Gastroenterology.

[42]  J. Reubi,et al.  Targeting CCK receptors in human cancers. , 2007, Current topics in medicinal chemistry.

[43]  G. Dockray,et al.  Gastrin: old hormone, new functions , 2004, Pflügers Archiv.

[44]  E. Rozengurt,et al.  Gastrin, CCK, signaling, and cancer. , 2001, Annual review of physiology.

[45]  S. Watson,et al.  Review article: gastrin and colorectal cancer. , 2000, Alimentary pharmacology & therapeutics.